{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:33:07Z","timestamp":1791329587441,"version":"4.3.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","award":["OCAY-18-774-OFIL"],"award-info":[{"award-number":["OCAY-18-774-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate flare risk when tapering or withdrawing biologic or targeted synthetic DMARDs (bDMARDs or tsDMARDs) compared with continuation in patients with inflammatory arthritis in sustained remission or with low disease activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Articles were identified in the Cochrane Library, PubMed, Embase and Web of Science. Eligible trials were randomized controlled trials comparing tapering and\/or withdrawal of bDMARDs and\/or tsDMARDs with the standard dose in inflammatory arthritis. Random effects meta-analysis was performed with risk ratio (RR) or Peto\u2019s odds ratio (POR) for sparse events and 95% CI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The meta-analysis comprised 22 trials: 11 assessed tapering and 7 addressed withdrawal (4 assessed both). Only trials with an RA or axial SpA (axSpA) population were identified. An increased flare risk was demonstrated when b-\/tsDMARD tapering was compared with continuation [RR 1.45 (95% CI 1.19, 1.77), I2\u2009=\u200942.5%] and potentially increased for persistent flare [POR 1.56 (95% CI 0.97, 2.52), I2\u2009=\u20090%]. Comparing TNF inhibitor (TNFi) withdrawal with continuation, a highly increased flare risk [RR 2.28 (95% CI 1.78, 2.93), I2\u2009=\u200978%] and increased odds of persistent flare [POR 3.41 (95% CI 1.91, 6.09), I2\u2009=\u200949%] were observed. No clear difference in flare risk between RA or axSpA was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A high risk for flare and persistent flare was demonstrated for TNFi withdrawal, whereas an increased risk for flare but not for persistent flare was observed for b-\/tsDMARD tapering. Thus tapering seems to be the more favourable approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Registration<\/jats:title>\n                  <jats:p>PROSPERO (CRD42019136905).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab902","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:08:22Z","timestamp":1638274102000},"page":"3107-3122","source":"Crossref","is-referenced-by-count":29,"title":["Risk of flare after tapering or withdrawal of biologic\/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4047-7175","authenticated-orcid":false,"given":"Line","family":"Uhrenholt","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital"},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg"},{"name":"Section for Biostatistics and Evidence-Based Research, Bispebjerg and Frederiksberg Hospital, Parker Institute , Copenhagen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[{"name":"Section for Biostatistics and Evidence-Based Research, Bispebjerg and Frederiksberg Hospital, Parker Institute , Copenhagen"},{"name":"Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital , Odense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred K H","family":"Dinesen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University , Aalborg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline H","family":"Liboriussen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University , Aalborg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine S","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aalborg University , Aalborg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital"},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Schlemmer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital"},{"name":"Department of Rheumatology, Randers Regional Hospital , Randers k"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen-Margrethe","family":"Hauge","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aarhus University Hospital"},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conni","family":"Skrubbeltrang","sequence":"additional","affiliation":[{"name":"Department of Medical Library, Aalborg University Hospital , Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital"},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"2022080317041482100_keab902-B1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"2022080317041482100_keab902-B2","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther"},{"key":"2022080317041482100_keab902-B3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40271-019-00403-9","article-title":"Tapering biologic therapy for rheumatoid arthritis: a qualitative study of patient perspectives","volume":"13","author":"Chan","year":"2020","journal-title":"Patient"},{"key":"2022080317041482100_keab902-B4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","article-title":"Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study","volume":"72","author":"van der Maas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B9","first-page":"CD010455","article-title":"Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity","volume":"5","author":"Verhoef","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2022080317041482100_keab902-B10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/annrheumdis-2017-212423","article-title":"Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis","volume":"77","author":"Henaux","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B11","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00296-020-04651-z","article-title":"Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis","volume":"40","author":"Vasconcelos","year":"2020","journal-title":"Rheumatol Int"},{"key":"2022080317041482100_keab902-B12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kez278","article-title":"Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review","volume":"59","author":"Schlager","year":"2020","journal-title":"Rheumatology"},{"key":"2022080317041482100_keab902-B13","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Comp\u00e1n","year":"2016","journal-title":"Rheumatology"},{"key":"2022080317041482100_keab902-B14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","article-title":"Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity","volume":"78","author":"Ye","year":"2018","journal-title":"Drugs"},{"key":"2022080317041482100_keab902-B15","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","article-title":"Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective","volume":"56","author":"Edwards","year":"2017","journal-title":"Rheumatology"},{"key":"2022080317041482100_keab902-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2022080317041482100_keab902-B17","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2022080317041482100_keab902-B18","author":"Higgins"},{"key":"2022080317041482100_keab902-B19","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2022080317041482100_keab902-B20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2022080317041482100_keab902-B21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables\u2013binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2022080317041482100_keab902-B22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"key":"2022080317041482100_keab902-B23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2022080317041482100_keab902-B24","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"2022080317041482100_keab902-B25","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2665-9913(19)30066-9","article-title":"Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial","volume":"1","author":"Verhoef","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2022080317041482100_keab902-B26","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/rheumatology\/kex315","article-title":"Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?","volume":"56","author":"Ibrahim","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2022080317041482100_keab902-B27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2022080317041482100_keab902-B28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jclinepi.2013.02.004","article-title":"The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses","volume":"66","author":"Mustafa","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2022080317041482100_keab902-B29","first-page":"63","article-title":"Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose","volume":"33","author":"Raffeiner","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022080317041482100_keab902-B30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022080317041482100_keab902-B32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet"},{"key":"2022080317041482100_keab902-B33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? a randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J Rheumatol"},{"key":"2022080317041482100_keab902-B34","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis\u202f: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biol Targets Ther"},{"key":"2022080317041482100_keab902-B35","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/art.41589","article-title":"Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022080317041482100_keab902-B36","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/art.40905","article-title":"Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open-label trial","volume":"71","author":"Sanmarti","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022080317041482100_keab902-B37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","article-title":"Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B38","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","article-title":"Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial","volume":"77","author":"l\u2019Ami","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B39","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00296-017-3749-7","article-title":"Maintenance of remission with combination etanercept\u2013DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access","volume":"37","author":"Pavelka","year":"2017","journal-title":"Rheumatol Int"},{"key":"2022080317041482100_keab902-B40","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/art.40196","article-title":"A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis","volume":"69","author":"Weinblatt","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022080317041482100_keab902-B41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","article-title":"Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial","volume":"75","author":"Fautrel","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B42","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.39626","article-title":"Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic randomized multicenter open-label controlled trial","volume":"68","author":"Ghiti Moghadam","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022080317041482100_keab902-B43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","article-title":"Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis","volume":"75","author":"van Vollenhoven","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B44","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/14397595.2015.1123349","article-title":"Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity - results from the ENCOURAGE study, a prospective, international, multicenter randomized study","volume":"26","author":"Yamanaka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2022080317041482100_keab902-B45","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"BMJ"},{"key":"2022080317041482100_keab902-B46","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/annrheumdis-2014-206149","article-title":"Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis","volume":"74","author":"Westhovens","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"Smolen","year":"2014","journal-title":"Lancet"},{"key":"2022080317041482100_keab902-B48","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"2022080317041482100_keab902-B49","doi-asserted-by":"crossref","first-page":"e000133","DOI":"10.1136\/rmdopen-2015-000133","article-title":"A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission","volume":"2","author":"Chatzidionysiou","year":"2016","journal-title":"RMD Open"},{"key":"2022080317041482100_keab902-B50","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10067-016-3413-8","article-title":"Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission","volume":"35","author":"El Miedany","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2022080317041482100_keab902-B51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","article-title":"Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study","volume":"75","author":"Haschka","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/annrheumdis-2011-200344","article-title":"Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study)","volume":"71","author":"Kaine","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022080317041482100_keab902-B53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-020-02188-x","article-title":"Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis","volume":"22","author":"Vinson","year":"2020","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab902\/42087943\/keab902.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/8\/3107\/45226658\/keab902.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/8\/3107\/45226658\/keab902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T17:07:32Z","timestamp":1659546452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/8\/3107\/6448788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,12,3]]},"published-print":{"date-parts":[[2022,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab902","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2021,12,3]]}}}